drugset / Trial / NCT02358993

Short-course Methenamine Hippurate for Prevention of Post-operative UTI

NCT02358993

Completed 201 enrolled University of Pennsylvania
RandomizedParallel-groupSingle-blindPrevention

Summary

The investigators will determine the efficacy of an innovative short regimen of methenamine hippurate on prevention of post-operative UTI in patients requiring short-term catheterization after pelvic reconstructive surgery through a single-blind, randomized controlled trial. Primary outcome will be the rate of symptomatic UTI within 3 weeks of catheter removal. The investigators will study cost-effectiveness, antibiotic resistance profiles, and adverse drug effects. Findings may reduce antibiotic use and nosocomial UTIs.

Timeline

Start
2014-12
Primary completion
2020-09-30
Completion
2020-09-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ciprofloxacin Small molecule 500 mg Oral
Subject Methenamine Hippurate Unknown 1 g Oral